SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.
The findings — presented at ASCO Genitourinary Cancers Symposium — highlighted the agent’s potential benefit among patients with papillary tumors without carcinoma in situ who did not respond to bacillus Calmette-Guèrin (BCG) therapy.
“I am pretty confident that we can at least rediscuss the way of conceiving new therapies in papillary tumors and potentially overcoming
